Bas Vorsteveld to leave Haleon at year’s end

He has been with Haleon since its creation, which resulted from the combination of three consumer health businesses

Haleon's vice-president and general manager for Great Britain and Ireland, Bas Vorsteveld, has announced his departure from the company.

Vorsteveld had been with Novartis Consumer Health and GSK since 2016, serving in various roles before the creation of Haleon.

“It's a wrap. After a journey of nearly 19 amazing years, I will be leaving Haleon at the end of this year to start a new chapter.

“Will be leaving a company that massively changed over time from the moment I started at Novartis Consumer Health. Did lead my teams through two integrations with GSK & Pfizer CH before separating,” he posted on LinkedIn.

He has not disclosed his next move but mentioned that he will share more about his future in the coming months.

Vorsteveld has also been serving as the president of the consumer healthcare association, PAGB, since December 2022.

Haleon is the culmination of the integration of three consumer health businesses, GlaxoSmithKline plc (GSK), Novartis, and Pfizer over the past decade. The company demerged from GSK in July 2022 and became an independent entity listed on the London and New York stock exchanges.

This year, Haleon won the Pharmacy Business Award for Branded Manufacturer of the Year, Vorsteveld receiving the award from pharmacy minister Stephen Kinnock.

Left to Right: Shailesh Solanki, Bas Vorsteveld, VP and General Manager for GB&I, Haleon, Stephen Kinnock MP, Kalpesh Solanki and Rory Bremner

Upon winning the award, he expressed: “Always great if the hard work of the team is being recognized.

We would like to thank all the pharmacists for their confidence and recognition of our strong partnerships and the way we deliver everyday health with humanity together.

Big thanks to my fantastic leadership team, who make the difference on a daily base for their teams, our customers and consumers in GBI.”

He noted that self-care has a lot of opportunities to help the government to relief the pressure on the NHS, with pharmacists playing a crucial role in this effort.